Request Demo
Last update 28 May 2025
AutoSynVax vaccine (Agenus/PureMHC)
Last update 28 May 2025
Overview
Basic Info
Drug Type Monoclonal antibody |
Synonyms AutologouscancervaccineAgenus, Neoantigen vaccine Agenus, ASV AGEN2017 + [1] |
Target- |
Action stimulants |
Mechanism Apoptosis stimulants, Immunostimulants |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
2
Clinical Trials associated with AutoSynVax vaccine (Agenus/PureMHC)NCT03673020
Phase 1a First-in-Human Study of Safety and Tolerability of ASV® AGEN2017 With QS-21 Stimulon® Adjuvant as a Single Agent in Subjects With Solid Tumor at Risk of Relapse Undergoing Observation as SOC Following Complete Surgical Resection
NCT02992977
A Phase 1 Study of Safety and Tolerability of AutoSynVax™ Vaccine as a Single Agent in Subjects With Advanced Cancer
100 Clinical Results associated with AutoSynVax vaccine (Agenus/PureMHC)
Login to view more data
100 Translational Medicine associated with AutoSynVax vaccine (Agenus/PureMHC)
Login to view more data
100 Patents (Medical) associated with AutoSynVax vaccine (Agenus/PureMHC)
Login to view more data
100 Deals associated with AutoSynVax vaccine (Agenus/PureMHC)
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Bladder Cancer | Phase 1 | United States | 16 May 2019 | |
| Breast Cancer | Phase 1 | United States | 16 May 2019 | |
| Colorectal Cancer | Phase 1 | United States | 16 May 2019 | |
| Head and Neck Neoplasms | Phase 1 | United States | 16 May 2019 | |
| Kidney Neoplasms | Phase 1 | United States | 16 May 2019 | |
| Melanoma | Phase 1 | United States | 16 May 2019 | |
| Non-Small Cell Lung Cancer | Phase 1 | United States | 16 May 2019 | |
| Soft Tissue Sarcoma | Phase 1 | United States | 16 May 2019 | |
| Uterine Cervical Cancer | Phase 1 | United States | 16 May 2019 | |
| Advanced cancer | Phase 1 | United States | 01 Jan 2017 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free